Sign in →

Test ID MIRI Mirikizumab, Serum


Ordering Guidance


Therapeutic drug monitoring of mirikizumab may be useful when assessing response to therapy is difficult or when patients need to be above a certain therapeutic concentration to improve the odds of a clinical response for therapy optimization, dose increases, or de-escalation or discontinuation of therapy.



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL Serum

Collection Instructions:

1. Draw blood immediately before next scheduled dose (trough specimen).

2. Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.


Reporting Name

Mirikizumab, S

Specimen Type

Serum

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Report Available

2 to 9 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MIRI Mirikizumab, S In Process

 

Result ID Test Result Name Result LOINC Value
623669 Mirikizumab, S In Process

Useful For

Assessing the response to mirikizumab therapy

 

Assessing the need for dose escalation

 

Evaluating the potential for dose de-escalation or discontinuation of therapy

 

Monitoring patients who need to be above a certain mirikizumab concentration to improve the odds of a clinical response for therapy optimization

Day(s) Performed

Wednesday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80299

Specimen Minimum Volume

Serum: 0.25 mL

Reference Values

Lower limit of quantitation = 0.5 mcg/mL

Method Name

Liquid Chromatography Mass Spectrometry (LC-MS)